What is Yunke Treatment?

Yunke treatment was actually developed in the 1990s. Currently, Yunke can treat diseases such as rheumatoid arthritis and osteoporosis. Although Yunke's treatment method is relatively new, its therapeutic effect is still quite obvious. Yunke treatment includes Yunke injection, Yunke intravenous drip and Yunke capsules, etc. These treatment methods only differ in the way they enter the human body, but their efficacy is actually relatively similar. When choosing Yunke treatment, everyone should go to a regular hospital, which is more appropriate.

Yunke is a world-first new drug for treating rheumatoid arthritis, osteoporosis and other diseases developed by a research team led by Li Maoliang, a famous drug development expert at the Chengdu Isotope Application Institute of the China Nuclear Power Research and Design Institute. After six years of hard work, the team successfully developed Yunke in the 1990s. It is one of the two domestically produced radionuclide drugs in China since the 1960s (other radionuclide drugs are all imported or generic drugs). "Yunke" is China's first radionuclide drug used in the clinical treatment of RA. It has won the national invention patent and the "National Key New Product" certificate and is protected by Chinese patents. It was approved by the State Food and Drug Administration in 2001 and can be circulated and used in clinical practice as a common drug.

"Yunke" injection

A dose + B dose as a single intravenous injection

Autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, hyperthyroidism with infiltrative exophthalmos and ophthalmoplegia, and psoriasis: one injection per day, 20 injections as a course of treatment, usually effective after about 10 injections. For the treatment of hyperthyroidism with exophthalmos, after 40 injections, two intravenous injections can be given per week. If appropriate, this can be maintained for 2-3 months to gradually improve the degree of exophthalmos.

Periarthritis of shoulder, gout, rheumatic pain: one intravenous injection per day, generally 10 injections can achieve the therapeutic effect. The number of intravenous injections can be increased or decreased according to the patient's condition.

All types of osteoporosis and osteitis deformans: two injections per week, and continue the treatment for six months to one year.

"Yunke" intravenous drip and "Yunke" capsules

Injection (200mg/bottle) Capsule (300mg/capsule)

Cancer bone metastasis: intravenous drip for 5 days (one bottle a day, each bottle is diluted with 250ml of normal saline, and the drip lasts for 2-3 hours), followed by oral capsules for 15 days (twice a day, 1-2 capsules each time, best taken two hours after a meal).

Hypercalcemia: intravenous drip for 5 days (same as the treatment for bone metastasis), followed by oral capsules for 3 months (1-2 capsules per day, best taken two hours after a meal).

All types of osteoporosis or osteoarthritis deformans: one bottle (200 mg) of intravenous drip per week, and persist in the treatment for half a year to a year; or one capsule (300 mg) orally daily, take it for one month and stop for two months, and persist for half a year to a year (depending on the condition).

For patients with more serious rheumatoid arthritis: use "Yunke" intravenous drip for 1-2 days, the usage is the same as the above "cancer bone metastasis" and then continue the treatment with "Yunke" injection.